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Accepted 29 April 2013Steroid cell tumors are rare sex cord tumors that account for
fewer than 0.1% of all ovarian tumors. Most of these tumors produce
steroids, particularly testosterone, and patients present clinically
with symptoms of virilization [1,2]. The tumors can be categorized
into three subtypes according to cell origin, stromal luteomas
arising from ovarian stroma, Leydig cell tumors arising from hilar
Leydig cells, and steroid cell tumors, not otherwise speciﬁed (NOS),
when the origin is unknown. Steroid cell tumors, NOS, are often
associated with virilization symptoms [1,2], although an associa-
tion with estrogenic manifestations has also been reported. We
present a rare case of steroid cell tumor, NOS, with an initial pre-
sentation of infertility.
A 29-year-old nulliparous woman presented to our outpatient
department for consultation regarding infertility. She had been
married for 4 years, but was not able to conceive. She had visited a
local hospital 3 years previously because of infertility; semen
analysis of her spouse and hysterosalpingography showed no ab-
normalities. Sonographic examination at that time revealed one 6-
cm ovarian tumor, but the patient declined further management.
The patient experienced intermittent vaginal bleeding and
irregular menstruation the previous year but no abdominal
discomfort or change in bowel habits. She visited our infertility
clinic and her endocrine proﬁle was checked as part of her infer-
tility workup. The patient had an elevated testosterone level
(1.35 ng/mL), but other hormone levels (follicle-stimulating hor-
mone, luteinizing hormone, prolactin, estradiol, progesterone)
were within normal limits. The patient was overweight (body
mass index 28.9) and had facial acne and signs of hirsutism* Corresponding author. Department of Obstetrics and Gynecology, National
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showed an enlarged clitoris and one fetal head-sized, ﬁrm adnexal
tumor. During the previous year, the patient experienced occa-
sional intermenstrual vaginal spotting and a change in the dura-
tion of menstruation from 1 week to 1 day. Detailed sonographic
examination at our clinic revealed one 10 cm  4 cm solid tumor
with heterogenous echogenicity and prominent ﬂow (Fig. 1). The
patient was then referred to our oncology clinic where tumor
markers were checked for suspected malignancy. Her serum
cancer antigen-125 level was slightly elevated (84.8 m/mL), with
normal levels of alpha fetoprotein (1.99 ng/mL), lactate dehydro-
genase (260 U/L), and carcinoembryonic antigen (1.84 ng/mL).
Computed tomography revealed normal kidneys and adrenal
glands, and one 10 cm  9 cm  6.5 cm solid ovarian mass with a
small amount of ascites (Fig. 2). A right ovarian tumor composed
of multilobulated bright yellowish nodules, with grossly diffuse
hemorrhage and gelatinous changes, was found on laparotomy
(Fig. 3). An immediate pathological frozen section revealed a ste-
roid cell tumor; a right adnexectomy was performed. A detailed
microscopic pathological examination showed a well-
encapsulated ovarian tumor composed of uniformly ovoid or
polygonal cells with small, centrally located nuclei, clumped
chromatin, and eosinophilic granular to clear vacuolated cyto-
plasm (Fig. 4). The tumor cells were dispersed into large lobules
and small nests by ﬁbrous septae and a capillary network,
respectively (Fig. 5). Foci of hemorrhage, focally prominent
vasculature, and degenerative changes were noted. There was
little mitosis (less than 1 per 10 high-power ﬁelds). The tumor
cells reacted strongly positive to Sudan III and Oil Red fat stains
(Fig. 6). Immunohistochemically, the tumor cells were positive to
alpha-inhibin and focally equivocally positive to S100, but nega-
tive to cytokeratin (AE1 and AE3), MDM-2, and HMB-45. Steroid
cell tumor, NOS was the ﬁnal diagnosis.The patient’s postoperative
course was smooth and she was discharged from the hospital on
the 4th day after surgery. Two weeks postoperatively, her serum
testosterone level had decreased to a normal level (0.32 ng/mL).
Her acne and facial hair also markedly diminished. She was
regularly followed for 24 months at our clinic, and her menstru-
ation cycle and hormone proﬁle were normal.by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. A sonogram revealed one pelvic mass with heterogeneous content.
Fig. 3. Cut surface of the tumor showed multilobulated, bright yellow nodules with
foci of gelatinous change and hemorrhage.
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accounting for 0.1% of all ovarian tumors [3,4]. These tumors are
typically solid with a yellow or orange section surface because of
intracytoplasmatic lipids. Generally, steroid cell tumors can origi-
nate from either the ovaries or ectopic adrenal glands [3e5]. Steroid
cell tumors, NOS, account for approximately 60% of the three ste-
roid cell tumor subtypes [6].
Steroid cell tumors, NOS, can be seen at all ages, and at a mean
age of 43 years. They cause androgenic and estrogenic manifesta-
tions in 50% and 10% of patients, respectively. The most common
manifestations of the hormonal effect from steroid cell tumor NOS,
are caused by testosterone production. Approximately 56e77% of
patients present with hirsutism and virilization symptoms, such as
a husky voice, male pattern baldness, acne, and increased facial and
chest hair [7]. Estradiol secretion occurs in 6e23% of patients andFig. 2. Computed tomographic scan showed one 10-cm hypervascular, heterogeneous
mass in the pelvic cavity.
Fig. 4. The tumor is composed of uniformly ovoid or polygonal cells with small,
centrally located nuclei and eosinophilic granular cells to clear vacuolated cytoplasm.
Fig. 5. The tumor cells are dissected into large lobules and small nests by ﬁbrous
septae and capillary network.
Fig. 6. Tumor cells are strongly positive for Oil Red fat stains.
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Approximately 25% of steroid cell tumors NOS, do not produce
hormones. An association with Cushing syndrome, which causes
hypokalemia and hypertension, has also been reported. In the
current case, the levels of serum adrenocorticotropic hormone,
cortisol, and electrolytes were all within normal ranges.
In contrast to the benign behavior of stromal luteoma and
Leydig cell tumors, steroid cell tumors NOS have a guarded prog-
nosis [9]. Although they are unilateral and amenable to unilateral
oophorectomy when apparently conﬁned to one ovary, as many as
20% of cases have tumor cell seeding and/or extension beyond the
ovary at the time of diagnosis. For women who have completed
childbearing, optimal staging with a total abdominal hysterectomy
and bilateral salpingooophorectomy is indicated. The predictive
pathological characteristics of malignancy proposed by Hayes and
Scully [8] are two or more mitotic ﬁgures per 10 high-power ﬁelds
(92%), size exceeding 7 cm (78%), Grade 2e3 nuclear atypia (64%),
necrosis (86%), and hemorrhage (77%) within the tumors. In their
series, 28.6% cases had features suggestive of malignancy. It is re-
ported that 25e43% of steroid cell tumors, NOS, are malignant [8].
In a young patient with clinical stage IA disease, such as the
patient in the current case, unilateral adnexectomy is primarily
considered because bilateral tumors only occur in approximately
6% of cases [8]. Adjuvant chemotherapy or radiation should beconsidered based on histopathology and survival staging [8] but
their therapeutic effect is poorly understood. Because ovarian
stromal tumors occur infrequently, chemotherapy regimens have
been conducted rarely in sporadically reported cases. Empirical
chemotherapy with bleomycin, etoposide, and cisplatin (BEP) for
ovarian stromal tumors, such as granulosa cell or Sertoli-Leydig cell
tumors, has been reported to be effective for metastatic disease [9e
11]. For malignant steroid cell tumors, NOS and stromal tumors as
well, BEP can be considered an effective and practical chemo-
therapy regimen. Our patient had none of the aforementioned risk
factors [8] except for a large tumor (exceeding 7 cm), and therefore
adjuvant therapy was not implemented. Empirical gonadotropin-
releasing hormone analogue treatment has been proposed for
gonadotropin-dependent virilizing steroid cell tumors [12]. Regular
monitoring of postoperative steroid hormone levels is suggested for
further adjuvant therapy.
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